Biolase, Inc. · OTC:BIOLQ
Biolase — Biolase Technology — 12th Annual Needham & Company Growth Conference (January 2010)
24 slides from Biolase's conference presentation, Jan 13, 2010
Slide 1: 12th Annual Needham & Company Growth Conference
12th Annual Needham & Company Growth Conference
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management's beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "e
Slide 3: Topics
Topics Product Overview Benefits - Better Dentistry Strategic and Market Size New Approach Tactical Marketing 1/13/2010 3
Slide 4: Product Overview (Henry Schein, BIOLASE)
Bo aye AHENRY SCHEIN’ , iebiin BIOLASE
Slide 5: ezlase: The Only Total Diode Dental Laser Solution
ezlase(tm): The Only Total Diode Dental Laser Solution 1/13/2010 5 ezlase Whitening and Pain Therapy Handpiece
Slide 6: Diolase for Chiropractic and Sports Medicine
Diolase 10 for Chiropractic and Sports Medicine Introduced to marketplace of approx. 60,000 chiropractors Dec. 2009 Provides highly effective, non- pharmaceutical pain relief and therapy High Intensity Laser Therapy (HILT) Based on proven ezlase(tm) platform New customized handpiece in development f
Slide 7: Deep Pocket Therapy with New Attachment
Deep Pocket Therapy with New Attachment(tm) using the Waterlase MD(tm) and Radial Firing Perio Tip(tm) Minimally invasive alternative therapy for moderate to advanced gum disease Promotes cementum-mediated periodontal ligament new- attachment to the root surface Minimally invasive FDA cleared Effect
Slide 8: Endodontics: Waterlase MD FDA-cleared
Endodontics: Waterlase MD is the only laser FDA-cleared for Access, Cleaning and Enlargement, and Disinfection 1/13/2010 8 Cleaning & Enlargement Access Disinfection
Slide 9: Introducing Waterlase MD Turbo
1/13/2010 9 Introducing Waterlase MD Turbo(tm)! Comparable speed to high speed drill A top reason for historic delay in purchase
Slide 10: Zone of Necrosis
Zone of Necrosis: The depth of tissue damaged around cut Waterlase: 5-10 Cell layers Diode laser: 15-25 Cell layers Scalpel: 100-300 Cell layers Electrosurgical Unit: 1000 - 1500 cell layers
Slide 11: Laser Surgery Changes the Healing Process
Laser Surgery Changes the Healing Process Barrier Clot Inflammation Tissue Regeneration Tissue Remodeling Tissue Regeneration Tissue Remodeling Normal Healing Cascade Laser Wound Healing Cascade Injury Healing Complete Healing Complete
Slide 12: A bur vs laser cut on your enamel
A bur vs laser cut on your enamel (hardest surface of the tooth) Visible microfractures Drill Waterlase SEM's courtesy of Loma Linda University School of Dentistry, Loma Linda, California, USA Bur cut Laser cut Note smooth smear layer of cut enamel and microfractures leads to bonding with smeared pa
Slide 13: Strategic Discussion
Strategic Discussion Waterlase Domestic - Core Market Potential Current and Potential Short-Term Penetration Long-Term Core Market Goal Strategic Priorities Today Adoption Curves and Timing New Programs - Tactical Examples 1/13/2010 13
Slide 14: Waterlase Domestic Penetration: $12 Billion Market
Waterlase Domestic Penetration If Every Dentist in America had a Waterlase $12 Billion Market - Our Largest Opportunity 1/13/2010 14 $0.3 Billion $1.6 Billion $4.1 Billion $4.1 Billion $1.9 Billion $12 Billion
Slide 15: 3% of Domestic Dentists Have Waterlase Today
Waterlase Domestic Penetration 3% of Domestic Dentists Have Waterlase Today Roughly $0.3 Billion Domestic Sales Primarily Over 6 Years 1/13/2010 15 $0.3 Billion $1.6 Billion $4.1 Billion $4.1 Billion $1.9 Billion 3% US Penetration Today
Slide 16: Penetration Varies With Over 10% in Some Markets
Waterlase Domestic Penetration Penetration Varies With Over 10% in Some Markets Potential $1.9 Billion - In 5 Years, $300MM Yr Avg. 1/13/2010 16 $0.3 Billion $1.6 Billion $4.1 Billion $4.1 Billion $1.9 Billion Penetration in various markets
Slide 17: Long-Term Goal Beyond Innovators and Early Adopters
Waterlase Domestic Penetration Long-Term Goal of Stretching Beyond Innovators and Early Adopters 1/13/2010 17 $0.3 Billion $1.6 Billion $4.1 Billion $4.1 Billion $1.9 Billion Penetration in various markets
Slide 18: Strategic Priorities Today
Strategic Priorities Today Accelerate expansion of core product into the domestic market: New products and product enhancements Applications and procedures Sales and marketing Supplemental: Diversification through business opportunities that require minimal resources /investment (existing IP and tur
Slide 19: Third Quarter & Nine-Month Revenue by Product
Third Quarter & Nine-Month Revenue by Product Sales by Product Line (in $Millions) Percent of Sales Q3 YTD Q3 YTD 9/30/09 9/30/09 9/30/09 9/30/09 Waterlase Family 7.0 18.0 58% 63 % Diolase Family 1.8 6.0 15% 19 % Total Lasers 8.8 24.0 73% 82 % Consumables, Service, Other 3.0 7.8 25% 13 % License and
Slide 20: Third Quarter & Nine-Month Operating Highlights
Third Quarter & Nine-Month Operating Highlights Q3 YTD 9/30/09 9/30/09 Net Revenue $12.1 $33.0 Gross Profit $5.8 $15.7 % revenue 48% 48% Operating Expenses $4.9 $17.3 % revenue 40% 52% Operating Profit (Loss) $0.9 ($1.6) % revenue 7% (5%) Net Income (Loss) $0.9 ($1.5) Earnings per share $0.04 $(0.06
Slide 21: Q3 Balance Sheet Highlights
Q3 Balance Sheet Highlights 9/30/09 6/30/09 Cash and Equivalents $3.9 $3.5 Net Working Capital $5.8 $4.0 Total Assets $23.3 $22.4 Stockholders' Equity $9.1 $7.7 ($ in millions)
Slide 22: Stock Market Data
Stock Market Data Stock Market Data
Slide 23: Summary
Summary 1/13/2010 23 Better Dentistry Speed Breakthrough Expansive Opportunity Medical Trends Pointing the Way Diversification Started at Biolase New Approach to Core Market Quantifiable Turn Signal - 5X Lead Generation Early Q4
Slide 24: Thank You
— BIOLASE ZAHIENRY SCHEIN’ > — — Thank You. ,
Biolase Technology — 12th Annual Needham & Company Growth Conference (January 2010) on 6ix